BUZZ-Jasper Therapeutics rises as BTIG initiates with 'buy' rating

Reuters07-08

** Shares of drug developer Jasper Therapeutics rise 11.5% to $23.58

** Brokerage BTIG initiates coverage with "Buy" rating and sets PT of $90, representing a four-fold upside to stock's last close

** Says co's experimental drug briquilimab is a product with attractive market potential in addressing chronic urticaria, a large market not well served by available therapies

** Briquilimab is currently in development to treat chronic urticaria or hives - a skin rash

** Says briquilimab could be positively differentiated from other therapies "on safety, efficacy, and a more convenient and less frequent dosing regimen, offering competitive commercial advantages" - BTIG

** Co to start an early-stage study to test briquilimab in asthma patients which BTIG says is attractive expansion opportunity and "is underappreciated and not currently reflected in the stock"

** Brokerage says it sees potential for briquilimab to be used in additional immunology and inflammatory indications that could drive further upside

** Including session moves, stock more than doubled YTD

(Reporting by Sneha S K in Bengaluru)

((Sneha.SK@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2449059067?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-07-08 21:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2449059067","market":"us","top_or_hot":-1,"title":"BUZZ-Jasper Therapeutics rises as BTIG initiates with 'buy' rating","media":"Reuters","content":"<html><body><p>** Shares of drug developer <a href=\"https://laohu8.com/S/JSPR\">Jasper Therapeutics</a>    rise 11.5% to $23.58  </p><p>   ** Brokerage BTIG initiates coverage with \"Buy\" rating and sets PT of $90, representing a four-fold upside to stock's last close  </p><p>   ** Says co's experimental drug briquilimab is a product with attractive market potential in addressing chronic urticaria, a large market not well served by available therapies</p><p>   ** Briquilimab is currently in development to treat chronic urticaria or hives - a skin rash</p><p>   ** Says briquilimab could be positively differentiated from other therapies \"on safety, efficacy, and a more convenient and less frequent dosing regimen, offering competitive commercial advantages\" - BTIG </p><p>   ** Co to start an early-stage study to test briquilimab in  asthma patients which BTIG says is attractive expansion opportunity and \"is underappreciated and not currently reflected in the stock\" </p><p>   ** Brokerage says it sees potential for briquilimab to be used in additional immunology and inflammatory indications that could drive further upside</p><p>   ** Including session moves, stock more than doubled YTD</p><p> (Reporting by Sneha S K in Bengaluru)</p><p>((Sneha.SK@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Jasper Therapeutics rises as BTIG initiates with 'buy' rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Jasper Therapeutics rises as BTIG initiates with 'buy' rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-08 21:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>** Shares of drug developer Jasper Therapeutics    rise 11.5% to $23.58     ** Brokerage BTIG initiates coverage with \"Buy\" rating and sets PT of $90, representing a four-fold upside to stock's last ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BUZZ","symbol_name":"VanEck Social Sentiment ETF","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2449059067","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2449059067","pubTimestamp":1720446836,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"** Shares of drug developer Jasper Therapeutics    rise 11.5% to $23.58     ** Brokerage BTIG initiates coverage with \"Buy\" rating and sets PT of $90, representing a four-fold upside to stock's last close     ** Says co's experimental drug briquilimab is a product with attractive market potential in addressing chronic urticaria, a large market not well served by available therapies   ** Briquilimab is currently in development to treat chronic urticaria or hives - a skin rash   ** Says briquilimab could be positively differentiated from other therapies \"on safety, efficacy, and a more convenient and less frequent dosing regimen, offering competitive commercial advantages\" - BTIG    ** Co to start an early-stage study to test briquilimab in  asthma patients which BTIG says is attractive expansion opportunity and \"is underappreciated and not currently reflected in the stock\"    ** Brokerage says it sees potential for briquilimab to be used in additional immunology and inflammatory indicat","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"BUZZ":"VanEck Social Sentiment ETF","JSPR":"Jasper Therapeutics"},"translate_title":"BTIG首次给予BUZZ-Jasper Therapeutics“买入”评级，股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BUZZ":1,"JSPR":1},"content_text":"** Shares of drug developer Jasper Therapeutics    rise 11.5% to $23.58     ** Brokerage BTIG initiates coverage with \"Buy\" rating and sets PT of $90, representing a four-fold upside to stock's last close     ** Says co's experimental drug briquilimab is a product with attractive market potential in addressing chronic urticaria, a large market not well served by available therapies   ** Briquilimab is currently in development to treat chronic urticaria or hives - a skin rash   ** Says briquilimab could be positively differentiated from other therapies \"on safety, efficacy, and a more convenient and less frequent dosing regimen, offering competitive commercial advantages\" - BTIG    ** Co to start an early-stage study to test briquilimab in  asthma patients which BTIG says is attractive expansion opportunity and \"is underappreciated and not currently reflected in the stock\"    ** Brokerage says it sees potential for briquilimab to be used in additional immunology and inflammatory indications that could drive further upside   ** Including session moves, stock more than doubled YTD (Reporting by Sneha S K in Bengaluru)((Sneha.SK@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.3","shortVersion":"4.28.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2449059067"}